New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 24, 2014
08:38 EDTAVNRAvanir to present data related to safety and efficacy of AVP-825
Avanir Pharmaceuticals announced that data related to the safety and efficacy of AVP-825, a Breath-Powered Nasal Delivery of Powdered Sumatriptan for the acute treatment of migraine, will be presented at the American Headache Society's 56th Annual Scientific Meeting. AVP-825 is an investigational drug-device combination product consisting of low-dose sumatriptan powder delivered intranasally utilizing a novel Breath-Powered delivery technology.
News For AVNR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 30, 2015
09:05 EDTAVNRAvanir reports positive results from Nuedexta study
Subscribe for More Information
June 17, 2015
09:03 EDTAVNRAvanir's AVP-825 device for migraine shows positive results
Avanir's COMPASS Phase IIIb, cross-over clinical trial comparing the efficacy and safety of AVP-825 22mg to sumatriptan 100mg tablets for the treatment of acute migraine across multiple attacks, showed that patients treated with AVP-825 achieved pain relief and pain freedom in significantly more migraine attacks at all time points from 15-90 minutes post-dose compared to sumatriptan tablets. A New Drug Application for AVP-825 has been accepted and is currently under review by the FDA with a Prescription Drug User Fee Act goal date of November 6.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use